The patient can consult the possibility of cancer chemoprevetion
in the case of expose to high-risk danger carcinoma
in the case of expose to high-risk danger carcinoma
The patient can consult the possibility of cancer chemoprevention
in the case of expose to high-risk danger carcinoma. Chemoprevention
of cancer is promising and hopeful branch of oncology. There are several
clinical trials, which confirm usefulness of this new approach to
oncological medicine. Although we are at the very beginning on this field,
we can use some knowledge in the clinical practise..
Several examples:
The present randomised trial for prevention of women with high risk
of breast carcinoma between Tamoxifen and Raloxifen (Evista) is not finished.
Tamoxifen is in use for women with high score of risk of breast carcinoma and
is in clinical use. Raloxifen is les carcinogen for uterus and is in use for
treatment of osteoporosis, but shows 78% lowering of breast carcinoma
for women using Raloxifen.
Sulindac sulphite and Sulindac sulphate is preventive agent for colon
carcinoma, especially for hereditary polyposis. The patients with
rheumatoid arthritis using antiflogistic agents has lower incidence
of colon cancer.
A clinical trial in Li-xian showed statistically significant influence
of some antioxidants and some trace elements for patients with dysplastic
changes. The field is too wide to describe all. The aim is to normalize
apoptosis during cancer development. (Apoptosis is guided cell deaths.
Proper healthy non-cancer cells committed suicide due to central
order - like in Socrates death!) The same and laboratory results with
genetically healthy material achieved apoptosis normalisation.
For example:
melanoblastic malignant cells become melanocytic back again.
